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The COVID-19 pandemic is currently being managed globally using pub-lic health measures to contain and mitigate its impact. The COVID-19 spares no national boundaries and is spreading rapidly in both high-in-
come and non-high-income countries [1]. The lack of approved therapies and 
the absence of a vaccine for COVID-19 have led to the repositioning of some 
existing medications with well-defined benefit-risk profiles in other indications. 
It is important to note that none of these medications have sufficient evidence 
on benefit-risk in COVID-19 patients, and should therefore be considered as experimental therapies, with 
an urgent need to collect data that will facilitate or prevent their use in COVID-19 patients – something 
that is already happening in many countries [2].
We searched four databases (ANZCTR, ClinicalTrials.gov, EU-CTR, ISRCTN) looking for randomized 
controlled trials (RCTs) aiming to assess the comparative efficacy of different treatment drug regimens for 
COVID-19 hospitalized patients, sponsored by non-industry institutions/organizations based in high-in-
come countries, that were registered on April 3, 2020. Two searches were conducted in each database 
using the terms ’coronavirus’ and ‘COVID-19’ as descriptors. In the two searches on ClinicalTrials.gov, we 
also used the following descriptors: Study type: ‘Interventional studies (clinical trials)’; Status: recruit-
ments: ‘Not yet recruiting’ and ‘recruiting’; Funder type: ‘NIH’, ‘Other US Federal Agency’ and ‘All others 
(individuals, universities, organizations)’. Table 1 shows the main characteristics of the eleven largest of 
these RCTs. The experimental medicines in all these trials are to be administered on top of the available 
standard of care.
THE STANDARD OF CARE ARM
At a time when emotions ride high and panic may prevail, it is important to strike the right balance in 
ensuring that, although public health and saving lives remain paramount, there is also the need to design 
RCTs in a manner that facilitates their conduct in both high-income and non-high-income countries, to 
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Table 1. Largest non-industry randomized controlled trials sponsored by organizations/institutions based on high-income-countries 
assessing experimental medicines (vs standard of care, with or without placebo) to treat COVID-19 hospitalized patients, that were 
recruiting or about to start enrollment; trials first registered on ANZCTR, ClinicalTrials.gov, EudraCT (accessed through EU-CTR) or 
ISRCTN, as of April 3, 2020
Name/Trial iD CouNTry (ies)/spoNsor TreaTmeNTs† N DesigN/sTaTus primary ouTCome measures*






1500 2-arm; parallel; 
open-label/Not yet 
recruiting
Inpatients: invasive mechanical 
ventilation or mortality.
Out-patients: hospital 
admission or death; up to 6 
weeks post-randomization
ACTT / NCT04280705, 
2020-01052-18
Denmark, Germany, Japan, 
Korea, Singapore, Spain, 
UK, USA/NIAID





Percentage of subjects 
reporting each severity rating 
on an 8-point ordinal scale 
(from 1.death to 8.not 
hospitalized, no limitations on 
activities); at day 15
COLCOVID /  
NCT04328480
Argentina/ECLA Colchicine ( ± lopina-
vir/ritonavir) vs SOC
2500 2-arm; parallel; 
open-label/Not yet 
recruiting





Sarilumab iv vs 
tocilizumab iv vs 
tocilizumab sc vs SOC
1000 4-arm; parallel; 
open-label/
Recruiting
Non-ICU patients: Survival 
without ventilator, at day 14; 
and WHO progression 
scale < or = 5, at day 4
ICU patients: Co-primary 
endpoints: 1. cumulative 
incidence of tracheal 
extubation, at day14; death, 
and 2. WHO progression scale 
>7, at day 4
COVID MED / 
NCT04328012
USA/Bassett Healthcare Lopinavir/ritonavir vs 
hydrochloro-quine vs 
losartan vs placebo
4000 4-arm; parallel; dou-
ble-blind/Not yet 
recruiting
NIAID Covid-19 ordinal 




Belgium, France, Germany, 
Luxembourg, the Nether-




vir ± IFNβ vs 
hydroxychloroquine vs 
SOC
3100 5-arm‡; adaptive; 
parallel; open-label/
Recruiting
Clinical status on a 7-point 
ordinal scale (from 1. not 
hospitalized, no limitations of 







Naproxen vs SOC 584 2-arm; parallel; 
open-label/Not yet 
recruiting








1500 2-arm; parallel; dou-
ble-blind/Not yet 
recruiting
All-cause mortality or the use 
of intubation and invasive 







510 2-arm; parallel; dou-
ble-blind/Not yet 
recruiting
Improvement on a 7-point 
ordinal scale (from 1. Death to 
7. Not hospitalized, no 





UK/University of Oxford Lopinavir/ritonavir vs 
dexamethasone vs 
IFNβ1a vs hydrochlo-
roquine § vs SOC
5000 5-arm‖; adaptive; 
parallel; open-label/
Recruiting





Argentina, Brazil, Canada, 
Germany, Indonesia, Iran, 
Norway¶, Peru, Qatar, South 




vir ± IFNβ-1a vs 
Hydroxychloroquine 






All-cause mortality (at 
discharge or death)
ECLA – Latin American clinical trials, Rosario, ICU – intensive care unit, IFNβ1a - interferon beta 1a, INSERM – French National Institute of Health 
and Medical Research, NIAID – US National Institute of Allergy and Infectious Diseases, SOC – standard of care, WHO – World Health Organization
*Mortality is a secondary outcome measure in ACTT, COVID MED, DISCOVERY and ORCHID. To be included in the table, the trial had to recruit, at 
least, 250 participants per arm. All RCTs that were described as triple- or quadruple-blind on ClinicalTrials.gov appear in the table as double-blind to 
be consistent with the EU-CTR terminology that only considers single- and double-blind trials.
†All experimental drug treatments and placebos are given on-top of standard of care.
‡It is not clear the number of arms in this trial since it has 4 on the EU-CTR (2020-000936-23; and 3300 participants) and 5 on ClinicalTrials.gov 
(NCT04315948; and 3100 participants).
§Hydroxychloroquine is mentioned in the EU-CTR and in the participant’s information sheet, although not in the study protocol [3].
‖If one or more drugs is not available or is contraindicated, random allocation will be adjusted between the remaining arms (2:1:1 or 2:1 ratio), as stat-
ed in the protocol [3].
¶It is not clear the number of arms that the trial will have in Norway. Thus, in the EU-CTR (2020-000982-18) the trial will assess only remdesivir vs 
hydroxychloroquine in 443 participants, but on ClinicalTrials.gov (NCT04321616), the trial will assess remdesivir vs hydroxychloroquine vs SOC in 
700 participants.
**The ISRCTN registry (ISRCTN83971151) stated ‘several’ thousands, whereas the EU-CTR (2020-001366-11) stated 100 000 participants (which 
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ultimately ensure global value and relevance. We are concerned that patients in many countries will re-
ject participation in trials with a control arm (receiving only the available standard of care, and placebo 
in masked trials), since the expectation will be to receive treatment with one of the experimental medi-
cines. The distress that prolonged quarantine commonly produces [4] could be enhanced in a patient on 
hospitalization with a diagnosis of the COVID-19 infection, who is then invited to participate in a RCT 
with the chance of not receiving any of the experimental medications when these could be prescribed 
off-label or received through compassionate use or an expanded access program [2] by refusing to par-
ticipate in the trial. The recent FDA approval of hydroxychloroquine sulfate and chloroquine phosphate, 
though limiting its usage for hospitalized COVID-19 patients when certain conditions are met [5], will 
further exacerbate this problem even outside the USA. Furthermore, healthcare professionals may be re-
luctant to get involved in trials in which their patients would receive only the standard of care, especially 
in sites where the number of severe hospitalized cases is high. All 49 trials found in our search, except 
eight, have a control arm (Appendix S1 in the Online Supplementary Document). The situation is made 
worse in RECOVERY by the anticipated random allocation ratio of 2:1:1:1, so participants will have a 
40% chance of not receiving any experimental medication [3]. Although we recognize the need for a con-
trol arm to enhance the comparative efficacy results of these RCTs, it is also possible that the recruitment 
into these trials could be jeopardized with inadequate enrolment – albeit how the information regarding 
the current lack of evidence-based targeted treatments is provided to potential participants by investiga-
tors is the key factor to ensuring recruitment. In a pandemic, the critical need to care for current patients 
should not negatively impact on research that will benefit future patients [6].
MORTALITY AS PRIMARY OUTCOME MEASURE
Since the mortality rate in hospitalized patients with COVID-19 pneumonia is significant, especially 
in patients over 60 years of age [7], we believe that RCTs with mortality as the single primary outcome 
measure (as is the case in COLCOVID, ENACOVID, SOLIDARITY and RECOVERY) will have the 
most relevance as death is a) perceived as the key patient-centered endpoint; “saving lives” is the fore-
most message to encourage citizens adherence to the strict social distancing mandate; and b) a hard 
(most robust) outcome measure, which is the easiest to register especially in non-high-income, but 
also during pandemics in high-income countries. Assessment of other non-mortality-based outcomes 
will likely be a problematical exercise due to the extremely difficult and sustained situation of high 
stress and workload for all healthcare professionals [8]. When the emotional, mental and physical 
well-being of healthcare professionals is under extreme pressure, confounded by the continuous ro-
tation of physicians and nurses caring for patients, seeking to register other primary and secondary 
outcome measures, may not only be feasible but also be unfair to the already exhausted healthcare 
professionals. Registration of 
non-mortality outcomes may not 
be an issue in hospitals with elec-
tronic health record systems, which 
should also be compatible with the 
central data management process-
es, something that could be an un-
surmountable hurdle in interna-
tional trials. We believe that even 
in healthcare systems that imple-
ment effective wellness activities to 
promote the resilience of health-
care professionals during the pan-
demic [9], the conduct of RCTs 
should not induce any additional 
adverse impact on their well-being.Photo: From the Jaffna Teaching Hospital, Jaffna; Sri Lanka (used with permission).
Involving sites from non-high-income countries in clinical trials and building their ca-
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Registering only deaths in international RCTs with an adaptive design facilitate the inclusion of sites from 
non-high-income countries, something essential in a pandemic. However, reaching confident conclusions 
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EPILOGUE
Most COVID-19 RCTs are being conducted or planned to start in high-income countries and China [10]. 
As shown in Table 1, with reference to hospitalized COVID-19 patients, there are very few large non-in-
dustry RCTs assessing experimental medicines sponsored by organizations/institutions based on high-in-
come-countries that could be suitable for non-high-income countries. To ensure the success and future 
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demics will only be satisfactorily controlled as a global effort. Involving sites from non-high-income 
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